A new study suggests that moderate coffee consumption may help prevent the recurrence of atrial fibrillation (AF) after treatment, challenging previous warnings that caffeine is detrimental to heart health. Researchers from the University of California, San Francisco (UCSF) conducted a randomized clinical trial called ‘DECAF,’ enrolling 200 adults with persistent AF. Participants were split into two groups: one continued regular coffee consumption, while the other abstained from caffeine for six months. Results showed that patients who drank coffee had a 39% lower risk of AF recurrence compared to those who avoided caffeine entirely.
The study, published in JAMA, involved monitoring participants through electrocardiogram recordings and tracking symptom severity and adverse events. While no significant differences in side effects were observed between groups, the researchers emphasized that the findings do not imply that all caffeine sources are beneficial. They cautioned against extrapolating these results to high-dose caffeine products like energy drinks, which have been linked to AF in some cases. Further research is needed to confirm the findings, as the study had limitations, including its open-label design and the specific population of participants who regularly consumed coffee before the trial.
Lead researcher Dr. Gregory Marcus, associate chief of cardiology for research at UCSF Health, stated that while the study’s results were expected to some extent, the magnitude of the protective effect was surprising. He noted that patients with AF or those concerned about developing it should not be discouraged from enjoying coffee if they currently do. However, Marcus also highlighted the importance of conducting more studies to validate these findings and explore potential lifestyle factors that could benefit atrial fibrillation patients.
Despite the promising results, the researchers acknowledged some limitations. The study only included individuals who had regularly consumed caffeinated coffee in the past five years and were willing to either continue or abstain from it. This means that people who experience caffeine-triggered AF and choose not to participate in the study were not represented. Marcus also mentioned that those who drank many cups of coffee daily were less likely to be open to reducing their intake, potentially skewing the study’s findings.
Furthermore, the study was conducted as an open-label trial, meaning participants and researchers knew which group they were in. This can introduce bias, as expectations about caffeine’s effects might influence behavior or symptom reporting. The trial focused on normal coffee consumption, not high-dose caffeine sources like energy drinks or supplements, and the authors warned against interpreting these findings as evidence that all caffeine is beneficial. Individuals should be cautious about assuming that these positive results apply to higher doses of caffeine or synthetic caffeinated products.